Showing that an experimental Alzheimer’s therapy delivers meaningful cognitive change is hard enough. But increasingly, AD drug sponsors face an additional challenge: making sure the tests capturing ...
Despite most monoclonal antibodies against Aβ in Alzheimer’s failed to demonstrate efficacy, the newest antibodies showed statistically significant clinical effects. We conducted a systematic review ...
Hosted on MSN
AAN: Multimodal lifestyle intervention consistently improves cognition in early dementia
WEDNESDAY, April 22, 2026 (HealthDay News) -- For patients with early Alzheimer disease and mild cognitive impairment, cognition is consistently improved with multimodal lifestyle interventions (MMLIs ...
Understanding the course of disease progression across the whole Alzheimer’s disease (AD) continuum including preclinical AD, mild cognitive impairment (MCI) due to AD, and AD dementia will help in ...
A putative amyloid-lowering agent, the blood pressure drug nilvadipine has proven ineffective in people with mild to moderate Alzheimer’s disease in a Phase 3 trial. In the September 24 PLoS Medicine, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results